RU2004128465A - Ингибиторы фарнезилпротеинтрансферазы как противоопухолевые агенты - Google Patents
Ингибиторы фарнезилпротеинтрансферазы как противоопухолевые агенты Download PDFInfo
- Publication number
- RU2004128465A RU2004128465A RU2004128465/04A RU2004128465A RU2004128465A RU 2004128465 A RU2004128465 A RU 2004128465A RU 2004128465/04 A RU2004128465/04 A RU 2004128465/04A RU 2004128465 A RU2004128465 A RU 2004128465A RU 2004128465 A RU2004128465 A RU 2004128465A
- Authority
- RU
- Russia
- Prior art keywords
- group
- alkyl
- substituted
- substituents
- groups
- Prior art date
Links
- 239000002246 antineoplastic agent Substances 0.000 title claims 24
- 108090000623 proteins and genes Proteins 0.000 title claims 2
- 229950008696 farnesil Drugs 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 239000003558 transferase inhibitor Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 claims 177
- 125000001424 substituent group Chemical group 0.000 claims 159
- 150000001875 compounds Chemical class 0.000 claims 142
- 229910052736 halogen Inorganic materials 0.000 claims 81
- 150000002367 halogens Chemical class 0.000 claims 81
- 125000001072 heteroaryl group Chemical group 0.000 claims 71
- 229910052799 carbon Inorganic materials 0.000 claims 65
- 125000000753 cycloalkyl group Chemical group 0.000 claims 58
- 125000003118 aryl group Chemical group 0.000 claims 57
- 125000003710 aryl alkyl group Chemical group 0.000 claims 52
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 47
- 229910052739 hydrogen Inorganic materials 0.000 claims 43
- 150000001721 carbon Chemical group 0.000 claims 37
- 125000004432 carbon atom Chemical group C* 0.000 claims 37
- 125000003386 piperidinyl group Chemical group 0.000 claims 37
- 239000003814 drug Substances 0.000 claims 35
- 125000004093 cyano group Chemical group *C#N 0.000 claims 33
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 31
- 125000005842 heteroatom Chemical group 0.000 claims 30
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 30
- 239000012634 fragment Substances 0.000 claims 29
- 125000003107 substituted aryl group Chemical group 0.000 claims 27
- 125000003342 alkenyl group Chemical group 0.000 claims 26
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 26
- 125000003545 alkoxy group Chemical group 0.000 claims 23
- 125000000547 substituted alkyl group Chemical group 0.000 claims 22
- 229940079593 drug Drugs 0.000 claims 21
- 206010028980 Neoplasm Diseases 0.000 claims 18
- 229910052757 nitrogen Inorganic materials 0.000 claims 17
- 201000011510 cancer Diseases 0.000 claims 16
- 229940123237 Taxane Drugs 0.000 claims 15
- 125000005843 halogen group Chemical group 0.000 claims 15
- 125000000623 heterocyclic group Chemical group 0.000 claims 15
- 229910052697 platinum Inorganic materials 0.000 claims 15
- 102000007399 Nuclear hormone receptor Human genes 0.000 claims 13
- 108020005497 Nuclear hormone receptor Proteins 0.000 claims 13
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 12
- 229930012538 Paclitaxel Natural products 0.000 claims 10
- -1 R 31 Chemical compound 0.000 claims 10
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 10
- 229960004562 carboplatin Drugs 0.000 claims 10
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 10
- 239000003112 inhibitor Substances 0.000 claims 10
- 238000004519 manufacturing process Methods 0.000 claims 10
- 229960001592 paclitaxel Drugs 0.000 claims 10
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 8
- 125000002883 imidazolyl group Chemical group 0.000 claims 8
- 229960004316 cisplatin Drugs 0.000 claims 7
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 6
- 125000001188 haloalkyl group Chemical group 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 5
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 5
- 230000000259 anti-tumor effect Effects 0.000 claims 5
- 125000004122 cyclic group Chemical group 0.000 claims 5
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 claims 5
- 229960005277 gemcitabine Drugs 0.000 claims 5
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 150000003384 small molecules Chemical class 0.000 claims 5
- 239000012453 solvate Substances 0.000 claims 5
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 5
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 4
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 4
- 125000000304 alkynyl group Chemical group 0.000 claims 4
- 125000003277 amino group Chemical group 0.000 claims 4
- 125000004104 aryloxy group Chemical group 0.000 claims 4
- 125000004429 atom Chemical group 0.000 claims 4
- 229940127089 cytotoxic agent Drugs 0.000 claims 4
- 229960003668 docetaxel Drugs 0.000 claims 4
- 125000004447 heteroarylalkenyl group Chemical group 0.000 claims 4
- 125000005312 heteroarylalkynyl group Chemical group 0.000 claims 4
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims 4
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 3
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims 3
- 125000005251 aryl acyl group Chemical group 0.000 claims 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 229940080856 gleevec Drugs 0.000 claims 3
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical group C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims 3
- 229940126601 medicinal product Drugs 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 3
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 3
- 102000016914 ras Proteins Human genes 0.000 claims 3
- 108010014186 ras Proteins Proteins 0.000 claims 3
- 229960003433 thalidomide Drugs 0.000 claims 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 3
- 102000014150 Interferons Human genes 0.000 claims 2
- 108010050904 Interferons Proteins 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 2
- 229940045799 anthracyclines and related substance Drugs 0.000 claims 2
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 239000011737 fluorine Substances 0.000 claims 2
- 229940022353 herceptin Drugs 0.000 claims 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 2
- 150000003949 imides Chemical class 0.000 claims 2
- 102000006495 integrins Human genes 0.000 claims 2
- 108010044426 integrins Proteins 0.000 claims 2
- 229940079322 interferon Drugs 0.000 claims 2
- 229940043355 kinase inhibitor Drugs 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 239000002777 nucleoside Substances 0.000 claims 2
- 125000003835 nucleoside group Chemical group 0.000 claims 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 2
- 229960004641 rituximab Drugs 0.000 claims 2
- 230000008054 signal transmission Effects 0.000 claims 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- 239000002525 vasculotropin inhibitor Substances 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 229940102550 Estrogen receptor antagonist Drugs 0.000 claims 1
- 229940123414 Folate antagonist Drugs 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 101150040459 RAS gene Proteins 0.000 claims 1
- 229940127395 Ribonucleotide Reductase Inhibitors Drugs 0.000 claims 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 1
- 102000004357 Transferases Human genes 0.000 claims 1
- 108090000992 Transferases Proteins 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 229940122803 Vinca alkaloid Drugs 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 229960005395 cetuximab Drugs 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims 1
- 229930013356 epothilone Natural products 0.000 claims 1
- 229960001433 erlotinib Drugs 0.000 claims 1
- 125000004030 farnesyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 230000003325 follicular Effects 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 1
- 150000002460 imidazoles Chemical class 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 208000025113 myeloid leukemia Diseases 0.000 claims 1
- 231100000590 oncogenic Toxicity 0.000 claims 1
- 230000002246 oncogenic effect Effects 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229960001972 panitumumab Drugs 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 108700042226 ras Genes Proteins 0.000 claims 1
- 239000000333 selective estrogen receptor modulator Substances 0.000 claims 1
- 229940095743 selective estrogen receptor modulator Drugs 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 208000017572 squamous cell neoplasm Diseases 0.000 claims 1
- 229940120982 tarceva Drugs 0.000 claims 1
- 125000002456 taxol group Chemical group 0.000 claims 1
- 229940063683 taxotere Drugs 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 0 C*1C=C[N+]([O-])=CC=C1 Chemical compound C*1C=C[N+]([O-])=CC=C1 0.000 description 3
- RJSZFSOFYVMDIC-UHFFFAOYSA-N CC(C)(C)OC(N(C)C)=O Chemical compound CC(C)(C)OC(N(C)C)=O RJSZFSOFYVMDIC-UHFFFAOYSA-N 0.000 description 1
- XKRJZKAIEPCDHI-UHFFFAOYSA-N CC(C)C(NC(c1ccccc1)=O)=O Chemical compound CC(C)C(NC(c1ccccc1)=O)=O XKRJZKAIEPCDHI-UHFFFAOYSA-N 0.000 description 1
- GVARNPQFAVKTPE-UHFFFAOYSA-N CC(C)C(Oc(cc1)ccc1F)=O Chemical compound CC(C)C(Oc(cc1)ccc1F)=O GVARNPQFAVKTPE-UHFFFAOYSA-N 0.000 description 1
- UYZOULGQIZPAPH-UHFFFAOYSA-N CC(C)C(c1cnc[n]1C)NC(OC(C)C)=O Chemical compound CC(C)C(c1cnc[n]1C)NC(OC(C)C)=O UYZOULGQIZPAPH-UHFFFAOYSA-N 0.000 description 1
- NMIDIXNPWNVHAW-UHFFFAOYSA-N CC(C)OC(N(CC1)CC[N-]1C1c2ncccc2C=C(Cc2cnc[n]2C)c2cc(Cl)ccc12)=O Chemical compound CC(C)OC(N(CC1)CC[N-]1C1c2ncccc2C=C(Cc2cnc[n]2C)c2cc(Cl)ccc12)=O NMIDIXNPWNVHAW-UHFFFAOYSA-N 0.000 description 1
- HDBPGUFVMVNSOC-UHFFFAOYSA-N CC(C)S(c(cc1)ccc1F)(=O)=O Chemical compound CC(C)S(c(cc1)ccc1F)(=O)=O HDBPGUFVMVNSOC-UHFFFAOYSA-N 0.000 description 1
- VZRYTCDXLCNXSS-UHFFFAOYSA-N CCOC(NC1C(C)C)=C[n]2c1cnc2 Chemical compound CCOC(NC1C(C)C)=C[n]2c1cnc2 VZRYTCDXLCNXSS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/085,896 | 2002-02-27 | ||
| US10/085,896 US20030229099A1 (en) | 2000-08-30 | 2002-02-27 | Novel farnesyl protein transferase inhibitors as antitumor agents |
| US10/325,896 US7342016B2 (en) | 2000-08-30 | 2002-12-19 | Farnesyl protein transferase inhibitors as antitumor agents |
| US10/325,896 | 2002-12-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2004128465A true RU2004128465A (ru) | 2005-09-27 |
Family
ID=27767345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2004128465/04A RU2004128465A (ru) | 2002-02-27 | 2003-02-25 | Ингибиторы фарнезилпротеинтрансферазы как противоопухолевые агенты |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US7342016B2 (OSRAM) |
| EP (1) | EP1492772A1 (OSRAM) |
| JP (1) | JP2005525356A (OSRAM) |
| KR (1) | KR20040098004A (OSRAM) |
| CN (1) | CN100537542C (OSRAM) |
| AR (1) | AR039557A1 (OSRAM) |
| AU (1) | AU2003215389B2 (OSRAM) |
| BR (1) | BR0308071A (OSRAM) |
| CA (1) | CA2477328A1 (OSRAM) |
| CO (1) | CO5611194A2 (OSRAM) |
| IL (1) | IL163673A0 (OSRAM) |
| MX (1) | MXPA04008303A (OSRAM) |
| NO (1) | NO20044053L (OSRAM) |
| NZ (1) | NZ534809A (OSRAM) |
| PE (1) | PE20031038A1 (OSRAM) |
| PL (1) | PL372335A1 (OSRAM) |
| RU (1) | RU2004128465A (OSRAM) |
| TW (1) | TW200303867A (OSRAM) |
| WO (1) | WO2003072549A1 (OSRAM) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ621449A (en) * | 2003-05-30 | 2015-07-31 | Genentech Inc | Treatment with anti-vegf antibodies |
| ATE417041T1 (de) * | 2003-08-07 | 2008-12-15 | Schering Corp | Neue farnesylproteintransferaseinhibitoren als antitumormittel |
| CA2568524A1 (en) * | 2004-05-28 | 2005-12-15 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
| JP2008501758A (ja) | 2004-06-09 | 2008-01-24 | グラクソ グループ リミテッド | ピロロピリジン誘導体 |
| EP1833481A1 (en) | 2004-12-14 | 2007-09-19 | Schering Corporation | Farnesyl protein transferase inhibitors and methods for treating proliferative diseases |
| AU2005319182A1 (en) * | 2004-12-21 | 2006-06-29 | Schering Corporation | Novel farnesyl protein transferase inhibitors as antitumor agents |
| CA2637572A1 (en) * | 2006-01-19 | 2007-07-26 | Schering Corporation | Piperazine derivatives as farnesyl protein transferase inhibitors |
| US20080090242A1 (en) * | 2006-09-29 | 2008-04-17 | Schering Corporation | Panel of biomarkers for prediction of fti efficacy |
| MY183404A (en) * | 2006-12-19 | 2021-02-18 | Genentech Inc | Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors |
| WO2010006432A1 (en) * | 2008-07-14 | 2010-01-21 | Queen's University At Kingston | Pharmaceutical compositions comprising ret inhibitors and methods for the treatment of cancer |
| US8975247B2 (en) | 2009-03-18 | 2015-03-10 | The Board Of Trustees Of The Leland Stanford Junion University | Methods and compositions of treating a flaviviridae family viral infection |
| US9227962B2 (en) | 2013-03-13 | 2016-01-05 | Boston Biomedical, Inc. | Heterocyclic substituted-3-heteroarylidenyl-2-indolinone derivative |
| US9187454B2 (en) * | 2013-03-13 | 2015-11-17 | Boston Biomedical, Inc. | Inhibitors of kinases and cancer stem cells, and methods of preparation and use thereof |
| CN105777646A (zh) * | 2016-04-08 | 2016-07-20 | 西南科技大学 | 一种新的5-碘-2-苯基-1-甲基咪唑的制备方法 |
| CN111454329A (zh) * | 2020-04-07 | 2020-07-28 | 哈尔滨师范大学 | 一种具有抗癌活性的异茚哚酮桥连环九肽及其制备方法 |
| WO2023071601A1 (zh) * | 2021-10-28 | 2023-05-04 | 天津市昕晨投资发展有限公司 | 地氯雷他定衍生物、其制备方法及其用途 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5089496A (en) * | 1986-10-31 | 1992-02-18 | Schering Corporation | Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies |
| US4826853A (en) | 1986-10-31 | 1989-05-02 | Schering Corporation | 6,11-Dihydro-11-(N-substituted-4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines and compositions and methods of use |
| US5393890A (en) | 1988-06-02 | 1995-02-28 | Ajinomoto Co., Inc. | Piperidine derivatives and hypotensives containing the same |
| AU8854091A (en) | 1990-10-10 | 1992-05-20 | Schering Corporation | Bis-benzo cyclohepta piperidylidene, piperidine and piperazine compounds, compositions and methods of use |
| GB9513371D0 (en) | 1995-06-30 | 1995-09-06 | Biocine Spa | Immunogenic detoxified mutant toxins |
| US5643909A (en) | 1993-04-19 | 1997-07-01 | Syntex (U.S.A.) Inc. | 10,11-Methanodibenzosuberane derivatives |
| US6075025A (en) * | 1993-10-15 | 2000-06-13 | Schering Corporation | Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
| US5721236A (en) | 1993-10-15 | 1998-02-24 | Schering Corporation | Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
| US5719148A (en) * | 1993-10-15 | 1998-02-17 | Schering Corporation | Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
| IL111235A (en) * | 1993-10-15 | 2001-03-19 | Schering Plough Corp | Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them |
| CZ292791B6 (cs) * | 1995-12-22 | 2003-12-17 | Schering Corporation | Tricyklické amidy, které se používají pro inhibici G-proteinové funkce a k léčení proliferativních onemocnění |
| US5874442A (en) | 1995-12-22 | 1999-02-23 | Schering-Plough Corporation | Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease |
| US6071907A (en) | 1996-09-13 | 2000-06-06 | Schering Corporation | Tricyclic compounds useful as FPT inhibitors |
| AU4337497A (en) * | 1996-09-13 | 1998-04-02 | Schering Corporation | Tricyclic compounds useful as fpt inhibitors |
| EP0929544B1 (en) | 1996-09-13 | 2004-11-10 | Schering Corporation | Tricyclic antitumor compounds being farnesyl protein transferase inhibitors |
| US5861395A (en) * | 1996-09-13 | 1999-01-19 | Schering Corporation | Compounds useful for inhibition of farnesyl proteins transferase |
| GB9801231D0 (en) * | 1997-06-05 | 1998-03-18 | Merck & Co Inc | A method of treating cancer |
| AU8253598A (en) | 1997-06-17 | 1999-01-04 | Schering Corporation | Novel n-substituted urea inhibitors of farnesyl-protein transferase |
| EP1156046A1 (en) | 1997-06-17 | 2001-11-21 | Schering Corporation | Benzo(5,6)cyclohepta(1,2-B)pyridine derivatives for the inhibition of farnesyl protein transferase |
| KR100640672B1 (ko) | 1997-06-17 | 2006-11-02 | 파마코페이아 드럭 디스커버리, 인크. | 파르네실 단백질 트랜스퍼라제의 억제에 유용한 벤즈피리도 사이클로헵탄 화합물 및 이를 포함하는 약제학적 조성물 |
| IL133393A0 (en) | 1997-06-17 | 2001-04-30 | Schering Corp | Novel tricyclic sulfonamide inhibitors of farnesyl-protein transferase |
| US5925648A (en) | 1997-07-29 | 1999-07-20 | Schering Corporation | Tricyclic N-cyanoimines useful as inhibitors of a farnesyl-protein transferase |
| AR021718A1 (es) | 1998-12-18 | 2002-07-31 | Schering Corp | Inhibidores de transferasa de proteina farnesilo. |
| ATE293622T1 (de) | 1998-12-18 | 2005-05-15 | Schering Corp | Farnesyl protein transferase inhibitoren |
| AU2292801A (en) * | 1999-12-22 | 2001-07-03 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Compositions and methods for treatment of breast cancer |
| SI1255537T1 (sl) | 2000-02-04 | 2006-10-31 | Janssen Pharmaceutica Nv | Inhibitorji farnezil protein transferaze za zdravljenje raka dojk |
| AR033680A1 (es) | 2000-08-30 | 2004-01-07 | Schering Corp | Compuestos triciclicos utiles como inhibidores de la farnesil proteino transferasa y su uso para la manufactura de medicamentos como agentes antitumorales |
| EP1453513A1 (en) * | 2001-12-03 | 2004-09-08 | Schering Corporation | Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer |
| ATE417041T1 (de) * | 2003-08-07 | 2008-12-15 | Schering Corp | Neue farnesylproteintransferaseinhibitoren als antitumormittel |
-
2002
- 2002-12-19 US US10/325,896 patent/US7342016B2/en not_active Expired - Fee Related
-
2003
- 2003-02-25 KR KR10-2004-7013310A patent/KR20040098004A/ko not_active Abandoned
- 2003-02-25 CN CNB038047209A patent/CN100537542C/zh not_active Expired - Fee Related
- 2003-02-25 CA CA002477328A patent/CA2477328A1/en not_active Abandoned
- 2003-02-25 PL PL03372335A patent/PL372335A1/xx not_active Application Discontinuation
- 2003-02-25 NZ NZ534809A patent/NZ534809A/en not_active IP Right Cessation
- 2003-02-25 AU AU2003215389A patent/AU2003215389B2/en not_active Ceased
- 2003-02-25 WO PCT/US2003/005479 patent/WO2003072549A1/en not_active Ceased
- 2003-02-25 IL IL16367303A patent/IL163673A0/xx unknown
- 2003-02-25 JP JP2003571255A patent/JP2005525356A/ja active Pending
- 2003-02-25 BR BR0308071-4A patent/BR0308071A/pt not_active IP Right Cessation
- 2003-02-25 AR ARP030100602A patent/AR039557A1/es unknown
- 2003-02-25 MX MXPA04008303A patent/MXPA04008303A/es unknown
- 2003-02-25 RU RU2004128465/04A patent/RU2004128465A/ru not_active Application Discontinuation
- 2003-02-25 EP EP03711214A patent/EP1492772A1/en not_active Withdrawn
- 2003-02-26 PE PE2003000190A patent/PE20031038A1/es not_active Application Discontinuation
- 2003-02-26 TW TW092104046A patent/TW200303867A/zh unknown
-
2004
- 2004-08-13 CO CO04079404A patent/CO5611194A2/es not_active Application Discontinuation
- 2004-09-24 NO NO20044053A patent/NO20044053L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN100537542C (zh) | 2009-09-09 |
| PL372335A1 (en) | 2005-07-11 |
| JP2005525356A (ja) | 2005-08-25 |
| NZ534809A (en) | 2007-12-21 |
| CO5611194A2 (es) | 2006-02-28 |
| AU2003215389A1 (en) | 2003-09-09 |
| BR0308071A (pt) | 2004-12-21 |
| AR039557A1 (es) | 2005-02-23 |
| PE20031038A1 (es) | 2004-01-10 |
| NO20044053L (no) | 2004-11-26 |
| US20040122018A1 (en) | 2004-06-24 |
| CN1630641A (zh) | 2005-06-22 |
| TW200303867A (en) | 2003-09-16 |
| WO2003072549A1 (en) | 2003-09-04 |
| EP1492772A1 (en) | 2005-01-05 |
| IL163673A0 (en) | 2005-12-18 |
| CA2477328A1 (en) | 2003-09-04 |
| US7342016B2 (en) | 2008-03-11 |
| MXPA04008303A (es) | 2005-11-23 |
| KR20040098004A (ko) | 2004-11-18 |
| AU2003215389B2 (en) | 2007-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022088662A (ja) | ツカレゾールまたはそのアナログを含む組成物 | |
| ES2576497T3 (es) | Compuesto de piperidina novedoso o sal del mismo | |
| EP3421039A1 (en) | Drug for cancer therapy characterized by administering combination between axl inhibitor and immune checkpoint inhibitor | |
| KR20210075992A (ko) | Sting 작동 화합물 | |
| KR20240142405A (ko) | 항체-약물 복합체 및 그의 용도 | |
| JP2005525315A5 (OSRAM) | ||
| CN102421429B (zh) | 癌症治疗用选择性ep4受体拮抗物质 | |
| PT1242401E (pt) | Agentes citotóxicos compreendendo taxanos e o seu uso terapêutico | |
| KR101993963B1 (ko) | 항 종양제 및 항 종양 효과 증강제 | |
| CZ296373B6 (cs) | Farmaceutický prípravek | |
| TW200817004A (en) | Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of mantle cell lymphomas | |
| TW200533339A (en) | Therapeutic synergy of anti-cancer compounds | |
| JP2024517945A5 (OSRAM) | ||
| JP2021514395A5 (OSRAM) | ||
| CA2797182A1 (en) | Methods of enhancing antibody-dependent cellular cytotoxicity | |
| KR20080004495A (ko) | 암을 치료하기 위한 조합물, 방법 및 조성물 | |
| KR20220015430A (ko) | 술폰아미드 화합물과 면역 조절제를 사용하는 암 병용 요법 | |
| JP2007501791A (ja) | 抗癌剤としての新規ファルネシルタンパク質トランスフェラーゼ阻害剤 | |
| US20030185831A1 (en) | Methods of treating cancer using an FPT inhibitor and antineoplastic | |
| JP2005511663A5 (OSRAM) | ||
| US20060199835A1 (en) | Neuroprotective and anti-proliferative compounds | |
| JP2001511191A (ja) | Ｈｔｌｖ−ｉによって引き起こされる白血病の治療で有用である２，２’−ビ−１ｈ−ピロール誘導体 | |
| JP2025166269A (ja) | 抗腫瘍効果を有する抗体薬物複合体の新規製造方法 | |
| CZ301053B6 (cs) | Farmaceutický prostredek a farmaceutické výrobky | |
| RU2328306C2 (ru) | Комбинированная противоопухолевая терапия замещенными производными акрилоилдистамицина и ингибиторами протеинкиназ (серин-/треонинкиназы) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20090302 |
|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20090302 |